



**BERYL DRUGS LIMITED**  
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.  
Tel./ Fax 0731-2517677  
E-mail : beryldrugs25@yahoo.com

**ANNEXURE I**

**Submission of Unaudited/ Audited Financial Result by Companies Other than Banks**

Part I (Rs in Lakhs) except per share data

**Statement of standalone Unaudited Result for the Quarterly/year ended 30/06/2022**

Particulars	Quarter ended			Year ended
	3 months ended (30-06-2022)	Preceding 3 months ended (31-03-2022)	Corresponding 3 months ended in the previous year (30-06-2021)	Previous year ended (31-03-2022)
(Refer Notes Below)	Unaudited	Audited	Unaudited	Audited
<b>1 Revenue From Operations</b>				
Net sales or Revenue from Operations	493.24	346.91	460.98	1460.37
Other operating revenues	3.59	5.13	3.85	16.49
<b>Total Revenue from operations (net)</b>	<b>496.83</b>	<b>352.04</b>	<b>464.83</b>	<b>1476.86</b>
<b>2 Expenses</b>				
(a) Cost of materials consumed	283.15	278.82	246.01	870.72
(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-25.22	-39.70	-4.23	-30.41
(d) Employee benefit expense	33.32	28.83	30.49	131.09
(e) Finance costs	12.59	9.93	11.16	43.68
(f) Depreciation and amortisation expense	24.66	27.12	29.87	108.65
(g) Other Expenses	146.15	112.86	121.68	448.16
<b>Total expenses</b>	<b>474.65</b>	<b>417.86</b>	<b>434.98</b>	<b>1571.89</b>
<b>3 Profit (loss) from operations before exceptional items and tax</b>	<b>22.18</b>	<b>-65.82</b>	<b>29.85</b>	<b>-95.03</b>
<b>4 Exceptional items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>5 Profit (loss) before tax</b>	<b>22.18</b>	<b>-65.82</b>	<b>29.85</b>	<b>-95.03</b>
<b>6 Tax Expense</b>				
Current tax	3.46	0.91	0.00	0.91
Mat Credit Entitlement	-3.46	0.00	0.00	0.00
Deferred tax	0.35	-19.29	-4.10	-30.04
<b>Total Tax Expenses</b>	<b>0.35</b>	<b>-18.38</b>	<b>-4.10</b>	<b>-29.13</b>
<b>7 Net Profit (loss) for the period from continuing operations</b>	<b>21.83</b>	<b>-47.44</b>	<b>33.95</b>	<b>-65.90</b>
<b>8 Net Profit (loss) from discontinuing operations before tax</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>9 Tax Expense of discontinuing operations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>10 Net Profit (loss) from discontinuing operations after tax</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>11 Net Profit (loss) for the Period</b>	<b>21.83</b>	<b>-47.44</b>	<b>33.95</b>	<b>-65.90</b>
<b>12 Other comprehensive income</b>	<b>-2.06</b>	<b>2.37</b>	<b>-3.72</b>	<b>2.32</b>
<b>13 Total Comprehensive Income</b>	<b>19.77</b>	<b>-45.07</b>	<b>30.23</b>	<b>-63.58</b>
<b>14 Details of equity share capital</b>				
Paid-up equity share capital	507.17	507.17	507.17	507.17
Face value of equity share capital	10.00	10.00	10.00	10.00
<b>15 Earnings per share (of Rs. 10 each)- for continuing operations</b>				
i Basic	0.43	-0.94	0.67	-1.30
ii Diluted	0.43	-0.94	0.67	-1.30

- Notes
- The above financial results have been prepared in accordance with the recognition and measurement principles stated therein prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Agreement Regulation.
  - The above results for the quarter ended 30th June 2022 which have been subjected to Limited Review by Statutory Auditors of the Company were reviewed and recommended by the Audit Committee and subsequently by the Board of Directors at its meeting held on 09th August, 2022 in terms of regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015, as amended.
  - The Income from Operations is from one segment namely "Pharmaceutical Industry" as per Ind AS 108 "Operating Segments".
  - The figures for the quarter ended March 31, 2022 are balancing figures between audited figures in respect of full financial year ended March 31, 2022 and the unaudited published figure up to December 31, 2021 being the end of third quarter of the financial year which were subjected to limited review.
  - The figures for the previous periods have been regrouped/ reclassified wherever necessary to confirm to current period classification.
  - Depreciation is provided on Written down value method on the estimated remaining useful lives of the assets.
  - Revenue from Operations is net of GST.
  - Earnings per Share amount is Shown in Rupee.

  
 For and behalf of the Board  
 Sanjay Sethu  
 Managing Director

Place Indore  
Date 09 08 2022